Reduced Time Per Patient - <1 minute per test with Cornea Sense vs. 5+ minutes for traditional methods, enabling more screenings and cost savings.
Simplified Process - One uniform metric for DED diagnosis; eliminates the need for multiple complex and time-consuming tests.
No Consumables Required - Non-invasive, pain-free, and non-contact testing eliminates recurring costs like cartridges or materials.
Enhanced Treatment Revenue - Early detection avoids severe outcomes like inflammation, corneal scarring, or ulcers, reducing risk of permanent damage.
Better Surgical Outcomes - Diagnosing DED pre-surgery (LASIK, cataracts) reduces risks of post-surgical complications and costs.
Prevent Disease Progression - Early detection avoids severe outcomes like inflammation, corneal scarring, or ulcers, reducing risk of permanent damage.
Reduced Treatment Costs - Early cases can use inexpensive treatments instead of costly prescription medications or surgeries.
Improved Treatment Efficacy - Treatments are more effective when applied before significant ocular surface damage occurs.
Investors, do you want to talk to us?
We are gathering feedback from possible investors, use the infromation below to contact us.
Address:
Cornea Sense R2B
Department of Electronics and Nanoengineering
Aalto University
Maarintie 8, 02150Espoo
Finland
Phone:
+358 50 470 7406
Email:
anton.chernenko (at) aalto.fi